Biologics, therapies made inside or of living cells, are a growing share of pharmaceutical sales. But the cost of these miracle treatments makes them unaffordable for many. New FDA guidance may help.
Insurance companies sometimes try to cut costs by substituting less expensive drugs for a specific drug prescription. That's raising problems in many cases, and actually causing harm.
Fixes for small pieces of massive problems show that overarching crises may be less hopeless than they appear.
Small-batch brewers are starting to tinker with biologic drugs to meet their own medical needs. A side effect of their success would be a disruption to how big pharma makes and distributes drugs.
A push towards prescribing generic medications rather than their branded equivalents, as flagged in the budget, may have benefits beyond simple cost savings.
The rising cost of drugs is more worrisome to most Americans than problems with Obamacare. Could proposals in California and Ohio help?
There is a window of opportunity for the least developed countries to develop their own pharmaceuticals industry.
Clinton, who named drug companies among her enemies in this week's debate, is pushing populist-inspired policies that could hamper the flow of new medicines.
The generic drug industry has become essential to developing countries that need access to cheaper drugs to treat their heavy burdens of communicable diseases.